Immucell PE ratio ICCC

Share price divided by earnings per share over the last twelve months, since 2012.

Today, Oct 23, 2026: 128×
10-year median: 44.0×
Against its 10-year history: 87th; percentile: 0 is its lowest day, 100 its highest
10-year range: 16.6× to 285×
Peer median: 12.8×

Immucell's PE ratio is 128× as of Oct 23, 2026: a share price of $10.25 against $0.08 of earnings per share over the last twelve months.

That is above its ten-year median of 44.0×, higher than on 87% of days in the last ten years.

Over that time it ranged from 16.6× in Nov 2016 to 285× in Nov 2022.

The median for 10 healthcare stocks of a similar size is 12.8×.

PE ratio over time

median 44×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	128×	22.8×	134×
2025	23.5×	18.0×	35.8×
2024	n/m a value too high to mean anything
2023	n/m a value too high to mean anything
2022	234×	57.1×	285×
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	90.7×	25.3×	96.1×
2016	28.3×	16.6×	30.0×
2015	22.8×	22.3×	122×
2014	86.3×	51.3×	114×
2013	51.3×	51.0×	184×
2012	129×	126×	500×

Against its peers

Companies in Healthcare nearest Immucell's size, closest first, today.

Company	PE ratio
ICCCImmucell	128×
KEQUKewaunee Scientific	11.9×
LFVNLifevantage	14.7×
SPROSpero Therapeutics	10.1×
APTAlpha Pro Tech	13.6×
ATNMActinium Pharmaceuticals	4.2×
PDEXPro DEX	15.1×
PLXProtalix BioTherapeutics	11.1×
NATRNatures Sunshine Products	12.0×
ELMDElectromed	20.1×
NEPHNephros	22.1×
Peer median	12.8×

Where Immucell ranks

#19of 20Diagnostics and research stocks with the lowest PE ratio

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Immucell

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.